Introduction {#S0001}
============

Community-acquired pneumonia (CAP) is a leading infectious cause of death in the UK.[@CIT0001] In the primary care setting, initial diagnosis is typically made on clinical judgment without radiological confirmation or knowledge of the causative organism.[@CIT0002] For patients presenting in primary care, the decision to treat in the community or refer for hospital admission requires an assessment of CAP severity. In severe CAP, delays in admission to the intensive care unit are associated with increased mortality.[@CIT0003],[@CIT0004]

Use of severity scores may act as an adjunct to clinical decision-making, aiding the identification of patients at high risk of death.[@CIT0005],[@CIT0007] However, many of these scores include parameters that cannot readily be assessed in primary care, such as urea included in the CURB65 score.[@CIT0008] Consequently, the CRB65 score has been developed for use in primary care.

The CRB65 score assigns one point to each of: confusion, raised respiratory rate (30 breaths per minute or more), low blood pressure (diastolic 60 mmHg or less, or systolic less than 90 mmHg) and age 65 years or more, and the total score can be used to predict 30-day mortality. CAP patients' 30-day mortality risk is then calculated as 0 (low risk -- less than 1% mortality risk), 1--2 (intermediate risk -- 1--10% mortality risk) and 3--4 (high risk -- more than 10% mortality risk).[@CIT0008]

In 2009, the CRB65 score was recommended for use in primary care by the British Thoracic Society (BTS) guidelines and quality standards on the management of CAP in adults.[@CIT0009] In December 2014, the CRB65 score was incorporated into National Institute for Health and Care Excellence (NICE) guidelines Pneumonia in Adults: Diagnosis and Management.[@CIT0010] The guidelines suggest CRB65 scores be used alongside clinical judgment in primary care, and that hospital-based care be considered for all patients with a CRB65 score of one or more, and particularly for those with a score of two or more. Furthermore, the guidelines recommend a 5-day course of a single antibiotic for patients with low-severity CAP, while a 7- or 10-day course of antibiotic therapy is recommended for moderate- to high-severity CAP. The use of CRB65 scores is also included in the most recent NICE quality standards for the management of pneumonia in adults,[@CIT0011] which states that adults diagnosed with CAP in primary care "should have a mortality risk assessment using the CRB65 score*"*. Finally, in January 2019, NICE released draft guidance on antimicrobial prescribing for CAP,[@CIT0012] in which antibiotic prescription is based on severity as determined by clinical judgement and CRB65 scores.

Despite studies on the accuracy of CRB65 scores in determining severity,[@CIT0006],[@CIT0013] and these scores being embedded in UK guidance,[@CIT0009],[@CIT0012] it is not known to what degree these scores are used in UK primary care. We set out to assess the use of CRB65 scores in patients diagnosed with CAP in UK primary care.

Materials And Methods {#S0002}
=====================

This retrospective observational database study aimed to investigate the management of CAP in primary care in the UK, focusing on the recording of CRB65 scores and prescription of antibiotics. The study was performed using electronic medical records obtained from the Optimum Patient Care Research Database (OPCRD: <https://opcrd.co.uk/>). The OPCRD is a quality-controlled, longitudinal, primary care, respiratory-focused database containing pseudonymised data from general practices in the UK. At the time of this study, it contained data of over 3.4 million patients and now contains data of 6.3 million patients from over 600 general practices. Because in the UK, people are required to register with a primary care physician in order to receive health care, UK primary care databases are widely considered to be essentially population-based.[@CIT0014]

The study protocol was approved by the Anonymised Data and Protocol Transparency (ADEPT) committee (ADEPT0817) and registered with the European Network of Centres for Pharmacoepidemiology and Phamacovigilance (ENCePP, EUPAS28667).

Record Selection {#S0002-S2001}
----------------

Primary care consultations in adults with a diagnostic code for CAP ([[Appendix 1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=211198.docx)) between 1 January 2009 and 31 December 2016 and with a minimum of 28 days of continuous medical record prior to and after the diagnoses were extracted from the OPCRD. The study period covered both the publication of the BTS CAP Guidelines in 2009[@CIT0009] and the publication of the NICE Quality Standard in December 2014.[@CIT0010] To maintain our focus on newly diagnosed cases of CAP managed in primary care, consultations were excluded if they had no recording of an antibiotic prescription on the day of diagnosis (on the assumption that they led to a hospital referral) or were summaries of past events. Consultations resulting in hospitalization were excluded from the main analysis as the timing of their hospitalization and data on their management was not available. However, this subset of patients was included in exploratory analysis of clinical details and CRB65 recording.

Consultations were grouped into episodes of CAP per patient. A new episode was defined as a consultation for CAP at least 180 days after any prior consultation for CAP for an individual patient. For each episode, an evaluation period consisting of an index date of the day of diagnosis, a baseline period of 28 days prior to diagnosis and outcome period of 28 days after diagnosis was considered.

Data Analysis {#S0002-S2002}
-------------

Data were analysed using R (version 3.4.0) and RStudio (version 1.0.143). The primary outcomes were CRB65 recording and class and length of antibiotic prescription. Demographic and clinical characteristics were summarised for both included and excluded CAP episodes. Statistical analysis utilised Chi-squared test for categorical variables, one-way ANOVA for continuous variables and Wilcox for differences in medians. Kendall's correlation was used to assess trends over time. Multivariable logistic regression was used to assess determinants of CRB65 recording. Variables showing an association with CRB-65 recording with a p-value of less than 0.2 in single variable analysis were included in the original logistic regression model. Variables showing no significant association (p\>0.05) were removed in a stepwise fashion.

Results {#S0003}
=======

A total of 49,863 new episodes of CAP were recorded in adults between 1 January 2009 and 31 December 2016, of which 36,011 had the minimum required continuous medical records ([Figure 1](#F0001){ref-type="fig"}). Of these, 21,802 (60.5%) were excluded because no antibiotic prescription was given in primary care and 5656 (15.7%) because the primary consultation was a summary of a past event. A further 3819 episodes had a referral to secondary care on the index date and so were only included in the exploratory analysis. The final study population, managed in primary care, consisted of 4734 discrete episodes of CAP from 4595 patients. Most patients had only one episode in the study period (4467, 97.2%) and the majority of episodes of CAP consisted of one consultation (3434, 72.5%). Of the 1300 episodes with more than one consultation, the majority had their second consultation in the outcome period (1134, 87.2%). The median time to second consultation in these episodes was 7 days (interquartile range \[IQR\]: 3--11). Of those with consultations for CAP in the outcome period, the majority had one (686, 60.5%) or two (263, 23.2%).Figure 1Flowchart of inclusion and exclusion criteria.

The incidence of CAP managed in primary care (n=4734) over the study period was 21.7 (95% confidence interval \[CI\]: 21.1--22.3) episodes per 100,000 patient-years in the database. Incidence of CAP managed in primary care declined over the study period (p\<0.001), and the absolute number of episodes had marked seasonality, with winter peaks in all years ([Figure 2](#F0002){ref-type="fig"}).Figure 2Trends in episodes of CAP in primary care from 2009 to 2016, n=4734.

Patient Characteristics {#S0003-S2001}
-----------------------

The study population of adult patients diagnosed with CAP (n=4734) had a mean age of 61.6 (standard deviation \[SD\]: ±19.3), and 46.0% (n=2179) were male. The cumulative incidence of CAP per 100,000 over the study period was similar between genders (male: 100.8, 95% CI: 96.6--105.1; females: 105.3, 95% CI: 101.2--109.4, [Figure 3](#F0003){ref-type="fig"}).Figure 3Cumulative incidence of episodes of CAP per 100,000 active patients in the OPCRD database, over the eight years of study.

Obesity was recorded in 24.5% (n=1158) and overweight in 28.6% (n=1355), with missing BMI data in 14.0%. 19.1% (n=904) current smokers and 36.5% (n=1729) were ex-smokers. The most common comorbidities prior to CAP diagnosis were gastro-oesophageal reflux disease (30.1% of which 23.3% \[1102/1427\] had active disease in the baseline period), cardiovascular disease (26.7%, n=1263), eczema (26.6% of which 0.5% \[23/1258\] had active disease), rhinitis (23.0% of which 8.5% \[401/1088\] had active disease) and asthma (22.9%, n=1086; [Table 1](#T0001){ref-type="table"}). A COPD diagnosis was recorded in 13.5% (n=639) of episodes.Table 1Baseline Demographic And Clinical Information For The Study Population And Excluded Episodes Referred To HospitalVariableIncluded Episodes Managed In Primary CareExcluded Episodes Referred To Hospitalp-Value\***Number of records, n (%)**4734 (100)3819 (100)**Age group:** n (%) 18--44 years1050 (22.2)418 (10.9)\<0.001 45--64 years1399 (29.6)758 (19.8) 65--84 years1720 (36.3)1773 (46.4) 85+ years565 (11.9)870 (22.8)**Mean age**61.6 (±19.3)70.1 (±18.1)\<0.001**Male gender:** n (%)2179 (46.0)1917 (50.2)\<0.001**Season: n (%)**\<0.001 Autumn1094 (23.1)890 (23.3) Winter1654 (34.9)1184 (31.0) Spring1209 (25.5)1029 (26.9) Summer777 (16.4)716 (18.7)**BMI class:** n (%)\<0.001 Underweight (\<18.5)179 (3.8)197 (5.2) Normal (≥18.5 and \<25)1377 (29.1)1261 (33.0) Overweight (≥25 and \<30)1355 (28.6)1014 (26.6) Obese (\>30)1158 (24.5)887 (23.2) Missing665 (14.0)460 (12.0)**BMI: Mean (SD)**27.4 (±6.7)27.0 (±6.7)0.012**Smoking status:** n (%)\<0.001 Non-smoker2046 (43.2)1582 (41.4) Current smoker904 (19.1)636 (16.7) Ex-smoker1729 (36.5)1489 (39.0) Missing55 (1.2)112 (2.9)**COPD diagnosed before or at index:** n (%)639 (13.5)806 (21.1)\<0.001**Asthma:** n (%) Diagnosed before or at index, unresolved1086 (22.9)726 (19.0)\<0.001 Resolved200 (4.2)129 (3.4)**Other chronic respiratory condition, ever diagnosed:** n (%)312 (6.6)545 (14.3)\<0.001**Bronchiectasis, ever diagnosed:** n (%)129 (2.7)154 (4.0)\<0.001**Cardiovascular disease, ever diagnosed:** n (%)1263 (26.7)1845 (48.3)\<0.001**Ischemic heart disease, ever diagnosed:** n (%)575 (12.1)876 (22.9)\<0.001**Congestive heart failure, ever diagnosed:** n (%)268 (5.7)412 (10.8)\<0.001**Myocardial infarction, ever diagnosed:** n (%)287 (6.1)431 (11.3)\<0.001**Hypertension, ever diagnosed:** n (%)87 (1.8)187 (4.9)\<0.001**Diabetes mellitus, ever diagnosed:** n (%)550 (11.6)714 (18.7)\<0.001**Rhinitis:** n (%) Active in baseline401 (8.5)406 (10.6)\<0.001 Ever diagnosed1088 (23.0)**Eczema:** n (%) Active in baseline23 (0.5)168 (4.4)\<0.001 Ever diagnosed1258 (26.6)**Eosinophilia in baseline:** n (%)648 (13.7)974 (25.5)\<0.001**Gastro-oesophageal reflux disease:** n (%) Active in baseline1102 (23.3)1307 (34.2)\<0.001 Ever diagnosed1427 (30.1)**Antibiotic prescription on day of diagnosis, n (%)**4734 (100)95 (2.5)[^1][^2]

Assessment Of CAP In Primary Care {#S0003-S2002}
---------------------------------

On the index date, a suspected organism was recorded for 13.5% (n=637) episodes, and 57.4% (n=2719) had details on the location or type of pneumonia. Blood pressure (17.6%, n=832), pulse rate (10.7%, n=508) and chest examination (9.1%, n=432) were the most frequently recorded observations on index date. Oxygen saturation was recorded in 7.1% (n=337) of episodes, blood tests in 5.4% (n=257) of episodes and urine tests in 1.3% (n=62). Radiology requests were recorded in 4.8% (n=228) on the day of diagnosis and 7.5% (354) in the 14 days following diagnosis.

### CRB65 Recording {#S0003-S2002-S3001}

CRB65 was not recorded in the evaluation period (28 days before and 28 days after the index date) in 4715 episodes of CAP. In 19 episodes (0.4%), CRB65 scores were recorded on index date, of which five episodes had a score of zero, 11 had a score of one and three had a score of two. Of these, 14 episodes also had CRB65 scores recorded in the baseline period (28 days before the index date) and one episode had a CRB65 score recorded in the outcome period (28 days after the index date).

In episodes where CRB65 scores were not recorded, 95 episodes had three components of CRB65 (confusion, respiratory rate, blood pressure and age) recorded individually, and one episode had all four components recorded. Further, two episodes for which CRB65 were recorded also had three or more components listed individually. The majority of episodes with three or more components recorded (79/98, 80.6%) had a calculated CRB65 score of less than two (range: 0--3). The least recorded components were presence/absence of confusion, recorded in 11 episodes (0.2%) and respiratory rate, recorded in 170 (3.6%) episodes.

The recording of both CRB65 and their components improved over time. The recording of CRB65 scores was significantly higher after the publication of the NICE guidelines in December 2014 (2015--2016: 17/740 \[2.3%; 95% CI: 1.3--3.7%\]) than beforehand (2009--2014: 2/3994 \[0.1%; 95% CI: 0.001--0.2%\]; p\<0.001; [Figure 4](#F0004){ref-type="fig"}). The two episodes with CRB65 score recorded prior to 2015 occurred in January and December 2014. Similarly, recording of at least three components of CRB65 was significantly higher in 2015--2016 (32/740 \[4.3%; 95% CI: 3.0--6.1%\]) than in the years prior (66/3994 \[1.7%; 95% CI: 1.3--2.1%\], p\<0.001, [Figure 4](#F0004){ref-type="fig"}).Figure 4Percentage of episodes recording CRB65 or at least three components of CRB65 per year.**Note:** Shaded areas: 95% confidence intervals.

In multivariable logistic regression, CRB65 scores or three or more components were more often recorded in episodes of CAP in older patients, those who had an LRTI consultation in the baseline period and those with eosinophilia ([Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}).Table 2Determinants Of Or Three Or More Components Of CRB65 Recording: Single Variable AnalysisCRB65 or 3 CRB65 Components Recorded: n (%)CRB65 Not Recorded: n (%)Risk Ratio95% Confidence Intervalsp-Value**Grouped year:** 2009--201350 (1.4)3443 (98.6)REFERENCE 2014--201665 (5.2)1176 (94.8)3.662.55--5.26\<0.001**Season:** Winter45 (2.7)1609 (97.3)REFERENCE Spring27 (2.2)1182 (97.8)0.820.51--1.320.411 Summer19 (2.4)758 (97.6)0.900.53--1.530.693 Autumn24 (2.2)1070 (97.8)0.810.49--1.320.387**Age:** 18--4413 (1.2)1037 (98.8)REFERENCE 45--6431 (2.2)1368 (97.8)1.790.94--3.400.071 65--8451 (3.0)1669 (97.0)2.391.31--4.380.003 85+20 (3.5)545 (96.5)2.861.43--5.700.001**Gender:** Male54 (2.5)2125 (97.5)REFERENCE Female61 (2.4)2494 (97.6)0.960.67--1.380.840**BMI:** Normal29 (2.1)1347 (97.9)REFERENCE Obese27 (2.3)1131 (97.7)1.110.66--1.860.700 Overweight40 (2.9)1315 (97.0)1.400.87--2.250.159 Under weight2 (1.1)648 (98.9)0.530.13--2.200.373 Missing17 (2.6)399 (97.4)1.210.67--2.190.520**Smoking status:** Non-smoker47 (2.3)1999 (97.7)REFERENCE Current smoker14 (1.5)890 (98.5)0.670.37--1.220.187 Ex-smoker51 (2.9)1678 (97.1)1.280.87--1.900.209 Missing3 (5.4)52 (94.5)2.370.76--7.390.130**≥1 consultations for LRTI in the 28 days prior to CAP diagnosis:** Present27 (5.1)502 (94.9)2.441.60--3.72\<0.001 Absent88 (2.1)4117 (97.9)REFERENCE**Antibiotics for LRTI in the 28 days prior to CAP diagnosis:** Present20 (4.8)400 (95.2)2.161.35--3.470.001 Absent95 (2.2)4219 (97.8)REFERENCE**Radiological assessment on index date:** Present8 (3.5)220 (96.5)1.480.73--2.990.278 Absent107 (2.4)4399 (97.6)REFERENCE**COPD before or on index date:** Present17 (2.7)622 (97.3)1.110.67--1.850.683 Absent98 (2.4)3997 (97.6)REFERENCE**Asthma before/on index date:** Present30 (2.5)1245 (97.5)0.960.63--1.440.836 Absent85 (2.4)3374 (97.6)REFERENCE**Chronic respiratory condition:** Present13 (4.2)299 (95.8)1.801.03--3.180.039 Absent102 (2.3)4320 (97.7)REFERENCE**Bronchiectasis:** Present7 (5.4)122 (94.6)2.311.11--4.870.025 Absent108 (2.3)4497 (97.7)REFERENCE**Cardiovascular disease:** Present39 (3.1)1224 (96.9)1.410.96--2.060.075 Absent76 (2.2)3395 (97.8)REFERENCE**Ischemic heart disease:** Present23 (4.0)552 (96.0)1.811.15--2.830.009 Absent92 (2.2)4067 (97.8)REFERENCE**Congestive heart failure:** Present8 (3.0)260 (97.0)1.250.61--2.530.543 Absent107 (2.4)4359 (97.6)REFERENCE**Myocardial infarction:** Present8 (2.8)279 (97.2)1.160.57--2.350.684 Absent107 (2.4)4340 (97.5)REFERENCE**Hypertension:** Present1 (1.1)86 (98.9)0.470.07--3.320.725 Absent114 (2.5)4533 (97.5)REFERENCE**Diabetes mellitus:** Present22 (4.0)528 (96.0)1.801.14--2.840.011 Absent93 (2.2)4091 (97.7)REFERENCE**Rhinitis:** Active11 (2.7)390 (97.3)1.120.61--2.080.686 Inactive15 (2.2)672 (97.8)0.890.52--1.530.711 Absent89 (2.4)3557 (97.6)REFERENCE**Eczema:** Active1 (4.3)22 (95.7)1.820.26--12.530.429 Inactive31 (2.5)1204 (97.5)1.050.70--1.580.829 Absent83 (2.4)3393 (97.6)REFERENCE**Eosinophilia:** Present28 (4.3)620 (95.7)2.031.34--2.03\<0.001 Absent87 (2.1)3999 (97.9)REFERENCE**Gastro-oesophageal reflux disease:** Active35 (3.2)1067 (96.8)1.440.97--2.140.072 Inactive7 (2.2)318 (97.8)0.980.45--2.100.950 Absent73 (2.2)3234 (97.8)REFERENCE[^3] Table 3Results Of Logistic Regression Modelling Of Determinants Of CRB65 Or Three Or More Components Of CRB65 RecordingRecorded n/N (%)Odds Ratio95% Confidence Intervalsp-Value**Year:** 2009--201468/3994 (1.7)Reference 2015--201647/740 (6.4)3.672.49--5.38\<0.001**Age group:** 18--4413/1050 (1.2)Reference 45--6431/1399 (2.2)1.640.87--3.280.141 65--8451/1720 (3.0)2.071.14--4.030.023 85+20/565 (3.5)2.561.26--5.360.010**LRTI consultation in baseline:** Present -- no antibiotics prescribed8/117 (6.8)3.471.50--7.010.001 Present -- antibiotics prescribed20/420 (4.7)2.181.28--3.530.003 Absent87/4197 (2.1)Reference**Diabetes mellitus:** Present22/550 (4.0)1.580.95--2.530.066 Absent93/4186 (2.2)Reference**Eosinophillia:** Present28/648 (4.3)1.721.09--2.640.016 Absent87/4086 (2.1)Reference[^4]

### Antibiotic Treatment {#S0003-S2002-S3002}

A consultation for lower respiratory tract infection (LRTI) was recorded in the baseline period in 11.2% of episodes, of which 79.4% (420/529) were prescribed antibiotics. On index date, 91.7% (n=4342) of episodes had a prescription for a single antibiotic and 8.3% (n=392) for multiple antibiotics. Amoxicillin was the most commonly prescribed single antibiotic (44.0%; 1908/4342), while amoxicillin plus clarithromycin was the most common combination where multiple antibiotics were prescribed (46.4%, 179/392, [Table 4](#T0004){ref-type="table"}). While four of the five episodes with a CRB65 score of zero were prescribed antibiotics in line with the draft NICE guidelines,[@CIT0012] this was the case for only four of the 14 records with CRB65 scores of 1 or 2 ([Table 5](#T0005){ref-type="table"}). Where the duration of antibiotic prescription on the day of CAP diagnosis was known, the mean duration was seven days (sd±2.6) and 76.5% (2599/3400) of episodes had a seven-day prescription.Table 4Antibiotic Prescriptions On Day Of CAP Diagnosis By CRB65 Score At IndexCRB65 ScoreNo CRB65 Score RecordedAll Episodes012n (%)**Single antibiotic592**4326**4342 (91.7)** **Penicillin261**2518**2527 (53.4)**  Amoxicillin15119011908 (40.3)  Co-amoxiclav110585587 (12.4)  Other0003232 (0.7) **Macrolide201**1136**1139 (24.1)**  Clarithromycin201882885 (18.7)  Erythromycin000232232 (4.9)  Azithromycin0002222 (0.5) **Tetracycline130**417**421 (8.9)**  Doxycycline130400404 (8.5)  Other0001717 (0.4) **Other000**255**255 (5.4)Multiple antibiotics021**389**392 (8.3)** Amoxicillin and erythromycin0002727 (0.6) Amoxicillin and clarithromycin021179182 (3.8) Co-amoxiclav and erythromycin00044 (0.08) Co-amoxiclav and clarithromycin0008989 (1.9) Other0009090 (1.9)**Total511347154734**[^5] Table 5Antibiotic Prescribing In Line With Proposed NICE GuidelinesCRB65 ScoreNICE Draft GuidelinesNumber of episodes, n (%)**0**First choice: Amoxicillin1 (20.0)Second choice: Clarithromycin, erythromycin or doxycycline3 (60.0)Other1 (20.0)**Total51--2**First choice: Amoxicillin and erythromycin or amoxicillin and clarithromycin3 (21.4)Second choice: Clarithromycin or azithromycin1 (7.1)Other10 (71.4)**Total**14**No score listed**NA: Those prescribed in line with CRB65 score 0--23643 (77.3)NA: Prescribed other therapies1072 (22.7)**Total4734**[^6]

Episodes where multiple antibiotics were prescribed were more likely to have a follow-on consultation in the outcome period for LRTI (38.3% \[95% CI: 33.4--43.3%\] vs 28.7% \[95% CI: 27.3--30.0%\], p\<0.001) or CAP (32.1% \[95% CI: 27.5--37.0%\] vs 23.2% \[95% CI: 22.0--24.5%\], p\<0.001) than those where single antibiotics were prescribed.

Exploratory Analysis Of Patients Managed In Primary Care And Those Referred To Secondary Care {#S0003-S2003}
---------------------------------------------------------------------------------------------

Patient characteristics of the study population managed in primary care differed significantly to the 3819 patients referred to hospital on day of CAP diagnosis ([Table 1](#T0001){ref-type="table"}). Those managed in primary care had a lower mean age, comprised a higher proportion of females and were more likely to be current or non-smokers than episodes referred to hospital, while those hospitalized were more likely to be ex-smokers ([Table 1](#T0001){ref-type="table"}). Episodes managed in primary care also had a lower proportion of cardiovascular disease (26.7% \[95% CI: 25.4--28.0%\] vs 48.3% \[95% CI: 46.7--49.9%\]; p\<0.001), pre-existing COPD (13.5% \[95% CI: 12.5--14.5%\] vs 21.1% \[95% CI: 19.8--22.4\]; p\<0.001) and other chronic respiratory conditions (6.6% \[95% CI: 5.9--7.3%\] vs 14.3% \[95% CI: 13.2--15.4%\]; p\<0.001) but a higher proportion pre-existing asthma (22.9% \[95% CI: 21.7--24.2%\] vs 19.0% \[95% CI: 17.8--20.3%\]; p\<0.001) than in episodes referred to hospital. There was no significant difference in the proportion of episodes where CRB65 was recorded between those managed in primary care (19, 0.4% \[95% CI: 0.24--0.63%\]) and those resulting in a hospital referral (12, 0.3% \[95% CI: 0.16--0.55%\]; p=0.63), though the median score was greater in those referred to hospital (1.0 \[IQR: 0.5--1.0\] vs 2.0 \[IQR: 1.0--2.0\], p=0.04).

Discussion {#S0004}
==========

This study demonstrates that, despite CRB65 scores being incorporated into BTS guidelines in 2009[@CIT0009] and NICE guidelines in 2014,[@CIT0010] CRB65 scores are not well documented by primary care physicians for CAP patients managed in primary care. CRB65 scores were completed on the day of diagnosis in only 0.4% of episodes, in the 28-day baseline period prior to diagnosis for 0.3% of episodes and in the 28-day outcome period after diagnosis in one episode. No increase in CRB65 recording was observed following the introduction of the BTS guidelines in 2009, and despite improvements in CRB65 recording following the NICE guidelines in 2014, CRB65 recording remained low throughout the study period. The recording of the components of the CRB65 score was also low, particularly respiratory rate and confusion. The low level of confusion recorded may reflect a reluctance to record an absence of confusion, or the difficulties of determining mental status in a short consultation. While the CRB65 score has good predictive value,[@CIT0007],[@CIT0013] its utility may depend on the population. A score of 1 in an otherwise healthy 65-year old may not require consideration of hospitalization, while in the elderly population confusion may be hard to differentiate from other pre-existing conditions.[@CIT0015]

The findings of our study are in line with a study of CRB65 use in admission decisions in a hospital in South Africa, where CRB65 was only being used in 1.6% of patients.[@CIT0016] This study concluded that, had CRB65 been used more frequently, fewer patients would have been hospitalized. Other studies have also shown that CAP severity scores are infrequently used in clinical practice.[@CIT0013]

In our study, CRB65 was more likely to be recorded in patients who were diagnosed with an LRTI in the 28 days prior to CAP diagnosis, who were over 85 years, or had eosinophilia. It may be therefore that CRB65 scores are being used more frequently to stratify patients perceived to be at increased risk of mortality. In addition to CRB65, other indicators such as poor functional status,[@CIT0017] oxygenation[@CIT0018] and comorbidities[@CIT0019] are also predictive of severity. Therefore, while CRB65 score recording was low, primary care physicians are likely using a wide range of indicators to inform their clinical judgement, including social factors[@CIT0020] not captured in our study. In our study, clinicians recorded a variety of additional indicators on the day of diagnosis for patients managed in primary care: pulse rate was recorded in 10.7% of episodes, oxygen saturation was recorded in 7.1% and blood tests were performed or requested in 5.4%. Notably, performing a chest examination was poorly recorded in our study (9.1%) possibly as this was considered a routine investigation and physicians reported results (57.4%) of the investigation instead.

While there was little difference in the proportion of episodes with CRB65 recorded between episodes managed in primary care and those referred to hospital, episodes of CAP managed in primary care were less likely to have comorbidities and were younger and where recorded had lower CRB65 scores than episodes resulting in referral to hospitalisation. This suggests that despite the low level of CRB65 recording, pneumonia in patients with pre-existing risk factors for adverse outcomes in pneumonia is more likely to be hospitalized.

Currently, NICE recommends that a five-day course of amoxicillin is considered for treatment of low-severity CAP, while dual antibiotic therapy of amoxicillin and a macrolide and a 7--10-day duration should be considered for moderate severity.[@CIT0011] The newly published draft NICE guidelines for antimicrobial prescribing for CAP[@CIT0012] provide more detail, providing alternative therapy in the event of penicillin allergy, estimated to affect approximately 10% of the population,[@CIT0021] and embedding the CRB65 scores into the decision-making process. In our study, amoxicillin was prescribed on the day of diagnosis as single antibiotic in 40.3% of episodes and in combination with a macrolide in 4.4% of episodes. While only a small number of episodes had CRB65 scores recorded, the observed differences between the draft NICE guidelines[@CIT0012] and the prescribing patterns in this study suggest a change in practice may be required. The majority of episodes in our study consisted of one consultation, suggesting that follow-up after antibiotic prescription is uncommon.

A recent study has suggested that a substantial proportion of antibiotic prescriptions given for common infections in primary care are for longer duration than guidelines suggest.[@CIT0022] Despite the NICE guidelines recommending that a five-day course of amoxicillin for low-severity CAP, the majority of prescriptions in our study were for seven days, as is recommended for low-severity CAP in the 2009 BTS guidelines.[@CIT0009],[@CIT0023]

The main limitation of this study is the observational nature. As an observational study based on medical records, this study is open to misclassification bias. A large proportion of identified CAP consultations (60.5%) did not have antibiotic prescriptions recorded on the day of diagnosis. Because prescriptions are generated automatically from the computer, antibiotic prescribing data are unlikely to be incomplete for such a large proportion of patients, although they may be missing for those treated at home or out of hours. Other potential reasons for the low rate of recorded antibiotic prescribing include misclassification of CAP or poor recording of hospital referral. It is the authors\' belief that the latter is the most plausible, and therefore these cases were excluded from the analysis. Patients referred to secondary care may receive antibiotic therapy in secondary rather than primary care and therefore antibiotic prescriptions may not be recorded in primary care records. Antibiotic prescription was markedly less recorded in those with hospitalization recorded (95/3819; 2.5%) compared to those managed in primary care (4734/26,536; 17.8%). Furthermore, it is unknown whether the low recording of CRB65 scores and the components of CRB65 is due to physicians not using these scores in primary practice, or whether they are used but not routinely recorded.

Conclusion {#S0005}
==========

While previous studies have shown that CRB65 scores are predictive of 30-day mortality, this is the first study in the UK to document the recording of CRB65 in primary care. We observed a low level of CRB65 recording in this study for patients managed in primary care and referred to secondary care. Further work is needed to assess feasibility of using CRB65 scores in primary care, GPs awareness of the inclusion of these scores in both the BTS and NICE guidelines and potential barriers to use of CRB65.
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[^1]: **Note:** \*Chi-squared or Fishers exact tests for all categorical variables, one-way ANOVA for continuous variables and Wilcox for median CRB65 score.

[^2]: **Abbreviations:** BMI, Body mass index; COPD, Chronic obstructive pulmonary disease.

[^3]: **Abbreviations:** LRTI, Lower respiratory tract infection; COPD, Chronic obstructive pulmonary disease.

[^4]: **Abbreviation:** LRTI, Lower respiratory tract infection.

[^5]: **Note:** Bold text and values are broad antibiotic classes, with the most frequently reported antibiotics in that class under them.

[^6]: **Note:** Data from NICE Guidelines.[@CIT0012]
